JP2021531822A5 - - Google Patents

Info

Publication number
JP2021531822A5
JP2021531822A5 JP2021523556A JP2021523556A JP2021531822A5 JP 2021531822 A5 JP2021531822 A5 JP 2021531822A5 JP 2021523556 A JP2021523556 A JP 2021523556A JP 2021523556 A JP2021523556 A JP 2021523556A JP 2021531822 A5 JP2021531822 A5 JP 2021531822A5
Authority
JP
Japan
Prior art keywords
heavy chain
light chain
antibody
nucleic acids
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531822A (ja
JP7332691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040843 external-priority patent/WO2020014143A1/en
Publication of JP2021531822A publication Critical patent/JP2021531822A/ja
Publication of JP2021531822A5 publication Critical patent/JP2021531822A5/ja
Priority to JP2023129892A priority Critical patent/JP2023145778A/ja
Application granted granted Critical
Publication of JP7332691B2 publication Critical patent/JP7332691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523556A 2018-07-08 2019-07-08 抗体の開発可能性が最大化された抗体ライブラリー Active JP7332691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023129892A JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862695065P 2018-07-08 2018-07-08
US62/695,065 2018-07-08
US201962822671P 2019-03-22 2019-03-22
US62/822,671 2019-03-22
PCT/US2019/040843 WO2020014143A1 (en) 2018-07-08 2019-07-08 Antibody libraries with maximized antibody developability characteristics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129892A Division JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Publications (3)

Publication Number Publication Date
JP2021531822A JP2021531822A (ja) 2021-11-25
JP2021531822A5 true JP2021531822A5 (https=) 2022-11-04
JP7332691B2 JP7332691B2 (ja) 2023-08-23

Family

ID=69102540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523556A Active JP7332691B2 (ja) 2018-07-08 2019-07-08 抗体の開発可能性が最大化された抗体ライブラリー
JP2023129892A Pending JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023129892A Pending JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Country Status (5)

Country Link
US (8) US10954508B2 (https=)
EP (1) EP3833685A4 (https=)
JP (2) JP7332691B2 (https=)
CA (1) CA3106115A1 (https=)
WO (1) WO2020014143A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US20230167165A1 (en) * 2021-07-07 2023-06-01 Specifica Inc. Antibody affinity maturation using natural liability-free cdrs
CA3244280A1 (en) * 2022-02-17 2023-08-24 Rules-Based Medicine Inc. SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS
WO2023232857A1 (en) * 2022-06-03 2023-12-07 Ichnos Sciences SA Common light chain antibody libraries
IL320284A (en) * 2022-10-18 2025-06-01 Tubulis Gmbh Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322614A1 (en) 1995-06-07 2011-05-18 Life Technologies Corporation Recombinational cloning using engineered recombination sites
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20060160178A1 (en) 2003-11-17 2006-07-20 Jonathan Rothberg Methods of generating antibody diversity in vitro
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
PE20110385A1 (es) * 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
EP3728705A4 (en) * 2017-12-18 2022-01-19 Charles River Laboratories, Inc. RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY

Similar Documents

Publication Publication Date Title
JP2021531822A5 (https=)
JP2023145778A5 (https=)
EP1032660B1 (en) Method of identifying binding site domains that retain the capacity of binding to an epitop
JP7332691B2 (ja) 抗体の開発可能性が最大化された抗体ライブラリー
US20100137156A1 (en) Construction and use of a functionally human antibody library with maximized repertoire diversity
McCormick et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig
JP2018520639A5 (https=)
Roque-Navarro et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method
RU99101121A (ru) Полипептиды, способные к образованию антигенсвязывающих структур со специфичностью к резус-d-антигенам, днк, кодирующая их, способы их получения и применение
JP2022505445A5 (https=)
JP2025508050A5 (https=)
CA2401342A1 (en) Human antibodies against eotaxin and their use
CN113603775A (zh) 抗人白介素-33单克隆抗体及其应用
US11390964B2 (en) Polyclonal mixtures of antibodies, and methods of making and using them
JP2025506683A5 (https=)
Parvari et al. Analyses of chicken immunoglobulin light chain cDNA clones indicate a few germline V lambda genes and allotypes of the C lambda locus.
JP2024521987A5 (https=)
JP2025011201A5 (https=)
Gueneau et al. Round optimization for improved discovery of native bispecific antibodies
JP2024523730A5 (https=)
WO2010130824A2 (en) Collections and uses thereof
Almagro et al. Novel approaches in discovery and design of antibody-based therapeutics
AR130792A1 (es) Proteínas de unión a antígeno
Harris et al. Reshaped Human Monoclonal Antibodies for Therapy and Passive Immunization
CN121362251A (zh) 抗il-5抗体、其药物组合物及用途